AJGP, October 2020: a focus on immunisation
The October 2020 edition of the Australian Journal of General Practice covers important topics in immunisation including:
- Immunisation and allergy in children and adults: A case based approach
- Seizures following vaccination in children: Risks, outcomes and management of subsequent revaccination
- Preparing the public for COVID-19 vaccines: How can general practitioners build vaccine confidence and optimise uptake for themselves and their patients?
- Maternal vaccinations
- BCG : An update on current Australian practices
Read the articles in full below:
Australian Journal of General Practice, October 2020
Australian Technical Advisory Group on Immunisation (ATAGI) COVID-19 Working Group
The role of the 澳大利亚免疫技术咨询小组 (ATAGI) is to provide independent advice to the Minister for Health on all matters relating to immunisation in Australia. In September 2020 ATAGI convened a new SARS-CoV-2 (COVID-19) working group. The key objectives of this group are to provide advice on COVID-19 immunisation programs and policies, to improve confidence in COVID-19 vaccines and to ensure equitable access to COVID-19 vaccines as they become available in Australia.
To learn more, please see below:
澳大利亚政府卫生部：澳大利亚免疫技术咨询小组 (ATAGI) COVID-19 工作组
Save the date for our first virtual Clinical Vaccinology Update!
MVEC is excited to announce that our first virtual Clinical Vaccinology Update (CVU) will be held on December 7, 2020.
Program details and ticketing information will be announced shortly.
EMA starts first rolling review of a COVID-19 vaccine in the EU
The European Medicines Agency (EMA) has begun a "rolling review" of the AstraZeneca Oxford SARS-CoV-2 vaccine candidate. Normal regulatory processes for medicines involve the submission of all safety and efficacy data to the Agency at the completion of clinical trials. A "rolling review" means that the Agency can begin evaluating data as it becomes available. By employing this method of approval, the regulation process will maintain its usual quality and safety standards, but be shorter than the usual process due to the time gained by reviewing data as it becomes available.
To learn more please read below:
EMA starts first rolling review of a COVID-19 vaccine in the EU
Frontiers in Immunology: Progress and Pitfalls in the Quest for Effective SARS-CoV-2 (COVID-19) Vaccines
With over 200 COVID-19 vaccine candidates currently in pre-clinical and clinical trials, the following article reviews what we know about the immune response to SARS-CoV-2 infection and explores the various vaccine platforms being utilised to develop a safe and effective vaccine. Potential issues including adverse effects and the need for mass production are also discussed, as well as the challenges of rapid and equitable vaccine delivery.
Read the article in full here:
新冠疫苗之路第15集：林恩·吉拉姆教授
在第 15 集中，我们的主持人 Nigel Crawford 副教授与 Lynn Gillam 教授进行了对话。林恩是一位接受过哲学和生物伦理学培训的临床伦理学家。她是墨尔本大学墨尔本人口与全球健康学院健康公平中心的教授；澳大利亚墨尔本皇家儿童医院儿童生物伦理中心学术主任。儿童生物伦理中心为临床医生提供有关患者护理问题的道德决策等支持。 Nigel 和 Lynn 将利用美国堪萨斯城儿童慈善医院的 John Lantos 博士在最近举行的生物伦理学电子会议上提出的观点框架，讨论 SARS-CoV-2 疫苗中提出的一些伦理问题儿童生命伦理中心主办：
- 认识到不做某事或不进行研究本身就是一个决定的重要性
- “太快不安全”的概念——有些步骤需要花他们一直采取的时间，有些事情可以更快地完成，认识到如果你什么都不做，你就会允许伤害发生
- 伦理委员会的作用和疫苗的开发方式，即在研究中使用更年轻、更健康的参与者，而不是患有最严重疾病的个人
- 儿童和老年人参与临床试验以及其伦理考虑的主要差异
- 当 SARS-CoV-2 疫苗上市时，全球公平获取疫苗的机会是什么？谁首先获得这些疫苗？应该如何做出这些决定？
- 公民陪审团在决定谁在大流行情况下优先获得疫苗方面的作用
- 强制接种疫苗
- 胎儿胚胎细胞系在疫苗开发中的应用
链接
- 澳洲金融评论：疫苗让人类面临下一次道德考验
- MVEC：用于疫苗开发平台的胎儿胚胎细胞
- 墨尔本大学：澄清可能的 COVID-19 疫苗的伦理问题
- BMC 公共卫生：让公众参与大流行病规划：一种深思熟虑的方法
- 社会科学与医学：公民陪审团在卫生政策决策中的运用：系统评价
- RCH Grand Rounds：不让大流行白白浪费——新冠危机如何带来更好的医疗保健服务
在这里收听该片段：
喇叭 - 苹果 - Spotify 音乐
NEJM: Evaluating and Deploying Covid-19 Vaccines — The Importance of Transparency, Scientific Integrity, and Public Trust
The following article published in the New England Journal of Medicine, discusses the importance of adhering to well-established and transparent regulatory processes when it comes to approving a COVID-19 vaccine. Reassuring the public with robust scientific evaluation from independent bodies, without interference from governments for the purposes of political advantage, is essential to promote public confidence and ensure the success of vaccination programs.
Read the article in full here:
New immunisation reference page: Identifying AEFI in diverse skin colour
The assessment of skin for clinical signs and symptoms is important when identifying adverse events following immunisation (AEFI). Since most dermatological assessment guidelines commonly refer to the presentation of symptoms in patients with light skin tones, the identification of AEFI in a timely manner in diverse skin colours can be challenging for immunisation providers.
Our new reference page details how symptoms such as pallor, cyanosis, erythema and urticaria may appear in diverse skin colours and discusses alternate methods of recognition. For more information please follow the link below:
MVEC: Identifying AEFI in diverse skin colour
新冠疫苗之路第 14 集：布鲁斯·杰林博士
在第 14 集中，我们的主持人 Nigel Crawford 副教授与 Bruce Gellin 博士进行了对话。布鲁斯是华盛顿萨宾疫苗研究所全球免疫部门的主席。萨宾疫苗研究所的使命是让疫苗更容易获得、促进创新并在全球范围内扩大免疫接种范围。 Bruce 于 2017 年担任这一职务，在此之前，他担任美国卫生与公众服务部国家疫苗计划办公室副助理部长，并担任世界卫生组织的技术和政策顾问，重点关注流感疫苗和全球疫苗接种问题。疫苗犹豫问题。布鲁斯还曾在疾病控制和预防中心 (CDC) 工作，为全球疫苗和免疫联盟提供咨询，并且是美国疫苗和免疫接种方面的主要发言人之一。他和奈杰尔在疫苗信心的背景下讨论了以下内容：
- 牛津阿斯利康试验最近停止，以及现有系统如何完全发挥作用
- “刀具事件”及其对疫苗安全性的持续影响，特别是从生产角度来看
- 确保免疫提供者了解疫苗开发过程非常重要，就好像他们不了解并且持怀疑态度一样，这会对疫苗的吸收产生巨大影响
- 公开披露在疫苗开发途径中的重要性
- 萨宾疫苗研究所如何应对疫苗犹豫的挑战
- 萨宾针对医护人员的“Boost”计划
- 疫苗使用后如何进行监测，也称为 IV 期监测
链接：
- 萨宾疫苗研究所
- 对话：停止牛津疫苗试验并不意味着它不安全——这表明他们正在遵循正确的程序
- 保罗·奥菲特的《刀具事件》
- 萨宾疫苗研究所：免疫倡导者
- 萨宾疫苗研究所：Boost
- 《柳叶刀》：绘制疫苗信心的全球趋势并调查疫苗接种的障碍：一项大规模回顾性时间模型研究
- 《柳叶刀》：是时候认真对待疫苗信心了
在这里收听该片段：
喇叭 - 苹果 - Spotify 音乐
New immunisation reference page: Injection site nodules
Injection site nodules are a rare but known adverse event following immunisation. They can occur following any vaccine and are most commonly asymptomatic and self resolving. Our new reference page describes what injection site nodules are and the implications on future immunisations.
To learn more follow the link below: